JP2018511325A - グルタミン酸オキサロ酢酸トランスアミナーゼ１（ｇｏｔ１）、その調製物および製造方法およびその使用 - Google Patents

グルタミン酸オキサロ酢酸トランスアミナーゼ１（ｇｏｔ１）、その調製物および製造方法およびその使用 Download PDF

Info

Publication number
JP2018511325A
JP2018511325A JP2017550936A JP2017550936A JP2018511325A JP 2018511325 A JP2018511325 A JP 2018511325A JP 2017550936 A JP2017550936 A JP 2017550936A JP 2017550936 A JP2017550936 A JP 2017550936A JP 2018511325 A JP2018511325 A JP 2018511325A
Authority
JP
Japan
Prior art keywords
got1
protein
preparation
polypeptide
sumo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017550936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511325A5 (enExample
Inventor
デイビッド ミレルマン，
デイビッド ミレルマン，
アハロン ラビンコフ，
アハロン ラビンコフ，
アンジェラ ルバン，
アンジェラ ルバン，
ギル ジョナ，
ギル ジョナ，
エリ ハズム，
エリ ハズム，
ヴラダス ブメリス，
ヴラダス ブメリス，
ネリジュス マカウスカス，
ネリジュス マカウスカス，
サウレ スドツィウヴィーネ，
サウレ スドツィウヴィーネ，
エレナ ナルモンタイテ，
エレナ ナルモンタイテ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2018511325A publication Critical patent/JP2018511325A/ja
Publication of JP2018511325A5 publication Critical patent/JP2018511325A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2017550936A 2015-03-31 2016-03-31 グルタミン酸オキサロ酢酸トランスアミナーゼ１（ｇｏｔ１）、その調製物および製造方法およびその使用 Pending JP2018511325A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140492P 2015-03-31 2015-03-31
US62/140,492 2015-03-31
PCT/IL2016/050346 WO2016157190A1 (en) 2015-03-31 2016-03-31 Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof

Publications (2)

Publication Number Publication Date
JP2018511325A true JP2018511325A (ja) 2018-04-26
JP2018511325A5 JP2018511325A5 (enExample) 2019-04-11

Family

ID=55795016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550936A Pending JP2018511325A (ja) 2015-03-31 2016-03-31 グルタミン酸オキサロ酢酸トランスアミナーゼ１（ｇｏｔ１）、その調製物および製造方法およびその使用

Country Status (11)

Country Link
US (1) US20180071369A1 (enExample)
EP (1) EP3277308A1 (enExample)
JP (1) JP2018511325A (enExample)
KR (1) KR20170132293A (enExample)
CN (1) CN107771217A (enExample)
AU (1) AU2016242298A1 (enExample)
BR (1) BR112017021016A2 (enExample)
CA (1) CA2979309A1 (enExample)
HK (1) HK1243329A1 (enExample)
RU (1) RU2017135552A (enExample)
WO (1) WO2016157190A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
RU2712193C1 (ru) * 2018-07-27 2020-01-24 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ лечения поражения нервной системы с помощью рекомбинантной глутаматоксалоацетаттрансаминазы
US11740211B2 (en) * 2020-01-31 2023-08-29 Waters Technologies Corporation LC/MS adduct mitigation by vapor deposition coated surfaces
CN116143898B (zh) * 2023-01-30 2026-03-24 翌圣生物科技(上海)股份有限公司 骨形态发生蛋白bmp-2重组蛋白、编码基因及其原核表达方法
CN118147225A (zh) * 2024-03-25 2024-06-07 华中农业大学 黄颡鱼去sumo化修饰体系及其构建方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514025A (ja) * 2002-01-07 2005-05-19 ライフセンサーズ、インク． タンパク質発現及び精製のための方法及び組成
EP2561889A2 (en) * 2002-08-01 2013-02-27 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
JP2013535207A (ja) * 2010-08-02 2013-09-12 バイオジェネリクス ゲーエムベーハー 活性型の可溶性シアリルトランスフェラーゼを作製及び精製する方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
EP1765857A2 (en) * 2004-07-02 2007-03-28 Metanomics GmbH Process for the production of fine chemicals
CA2585798A1 (en) * 2004-12-17 2006-06-17 Metanomics Gmbh Process for the control of production of fine chemicals
US8119369B2 (en) 2004-12-30 2012-02-21 Lifesensors, Inc. Human SUMO-3 for enhancing protein expression
US20100048480A1 (en) * 2006-11-22 2010-02-25 Bettina Bommarius Production of anti-microbial peptides
JP5469786B2 (ja) * 2006-12-29 2014-04-16 ライフセンサーズ、インク． タンパク質の発現増強および精製の方法および組成
EP2714727B1 (en) * 2011-05-24 2014-10-22 Asociación Centro de Investigación Cooperativa en Biociencias-CIC Biogune High affinity sumo traps

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514025A (ja) * 2002-01-07 2005-05-19 ライフセンサーズ、インク． タンパク質発現及び精製のための方法及び組成
EP2561889A2 (en) * 2002-08-01 2013-02-27 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
JP2013535207A (ja) * 2010-08-02 2013-09-12 バイオジェネリクス ゲーエムベーハー 活性型の可溶性シアリルトランスフェラーゼを作製及び精製する方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. J., 1990, 270(3), PP.651-657, JPN6020000447, ISSN: 0004332872 *
INT. J. MOL. SCI., 2015 FEB, 16(2), PP.3226-3236, JPN6020000440, ISSN: 0004332868 *
PROTEIN EXPR. PURIF., 2012, 81(1), PP.25-32, JPN6020000443, ISSN: 0004332870 *
PROTEIN EXPR. PURIF., 2014, 99, PP.18-26, JPN6020000445, ISSN: 0004332871 *
PROTEIN SCI., 2006, 15(1), PP.182-189, JPN6020000441, ISSN: 0004332869 *

Also Published As

Publication number Publication date
HK1243329A1 (zh) 2018-07-13
CN107771217A (zh) 2018-03-06
WO2016157190A1 (en) 2016-10-06
US20180071369A1 (en) 2018-03-15
EP3277308A1 (en) 2018-02-07
AU2016242298A1 (en) 2017-10-19
KR20170132293A (ko) 2017-12-01
RU2017135552A (ru) 2019-04-30
RU2017135552A3 (enExample) 2019-07-24
CA2979309A1 (en) 2016-10-06
BR112017021016A2 (pt) 2018-07-03

Similar Documents

Publication Publication Date Title
TWI868683B (zh) 一種用於癌症、肥胖、代謝失調、及相關併發症與合併症之精胺酸消耗劑的組成物及用途
EP0293793B1 (en) Polypeptide and production thereof
JP7058670B2 (ja) 増殖分化因子１５融合タンパク質
US20180071369A1 (en) Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
JP5738636B2 (ja) Ｔａｔ−ｈｏｘｂ４ｈタンパク質を含む造血幹細胞の骨髄から末梢血液への動員を促す薬、および、造血幹細胞移植患者、放射線治療患者または化学療法患者の回復時間を改善するための薬
JP6742300B2 (ja) ｒＨｕ−ＧＣＳＦの精製のための新規プロセス
WO2014178078A2 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
KR20130122764A (ko) 항암 융합 단백질
JP7187040B2 (ja) 高ホモシステイン血症およびホモシスチン尿症の患者を処置するための、ヒト酵素介在性のホモシステイン枯渇
EP3400241A1 (en) Modulation of afucosylated species in a monoclonal antibody composition
CA3010600A1 (en) Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
CZ98297A3 (cs) Způsob purifikace keratinocytových růstových faktorů
CN101402688A (zh) 一种融合蛋白及其编码基因与应用
Wang et al. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli
JP2005535353A (ja) Ｃ４ｂｐスカフォールドを使用した、多量体融合タンパク質の産生
EP0550769A1 (en) Hematopoietic stem cell multiplier
CN105085658B (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
CN110894239A (zh) 一种靶向egfr二聚体界面的人源化双特异性纳米抗体
RU2575598C9 (ru) Способ получения белка альфа5-интерферона
JP2012511309A (ja) Ｅｃ−ｓｏｄのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質
Song et al. High-efficiency production of bioactive recombinant human fibroblast growth factor 18 in Escherichia coli and its effects on hair follicle growth
JP2026509661A (ja) ヘリコバクター・ピロリ由来のフコシルトランスフェラーゼ変異体
CN1055009A (zh) 人的碱性fgf突变蛋白质的制备
JP2012516878A (ja) 精製プロセス
Su et al. High-level expression of human stem cell factor fused with erythropoietin mimetic peptide in Escherichia coli

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200827